Chie Sugimoto, Hiroyoshi Fujita, Hiroshi Wakao. Harnessing the Power of Mucosal-Associated Invariant T (MAIT) Cells in Cancer Cell Therapy. Biomedicines. 2022. 10. 12
Chie Sugimoto, Yukie Murakami, Eisuke Ishii, Hiroyoshi Fujita, Hiroshi Wakao. Reprogramming and redifferentiation of mucosal-associated invariant T cells reveal tumor inhibitory activity. eLife. 2022. 11
Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto KJ, Nakazato T, Fujita H, Kimura Y, Fujioka I, et al. Potential role for second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis. Oncology reports. 2019. 42. 6. 2836-2843
Iriyama N, Tokuhira M, Sato E, Sugimoto KJ, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, et al. Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematological oncology. 2019. 37. 3. 323-325
Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, et al. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. Medical oncology (Northwood, London, England). 2018. 35. 11. 142-142
I. Fujioka, T. Takaku, N. Iriyama, M. Tokuhira, E. Sato, M. Ishikawa, T. Nakazato, K-J. Sugimoto, H. Fujita, N. Asou, et al. ANALYSIS OF VASCULAR ADVERSE EVENTS IN TKI TREATED JAPANESE CML PATIENTS: RETROSPECTIVE LARGE COHORT STUDY OF CML COOPERATIVE STUDY GROUP. HAEMATOLOGICA. 2017. 102. 435-436
Makoto Watanabe, Akio Koyama, Takeshi Saito, Kouich Terasawa, Hiroyoshi Fujita, Kazuo Saito. [Dr Leonor Michaelis and early days of Hokkaido University School of Medicine; episodes among three medical researchers in the roaring twenties]. [Hokkaido igaku zasshi] The Hokkaido journal of medical science. 2011. 86. 4-5. 203-8